Real-world data: Givlaari is safe, effective for acute hepatic porphyria patients
Givlaari safely led to a complete resolution of annual attacks in people with AHP, real-world data from a case series study in Italy shows.| Porphyria News
The Post-Market Shift: From Sites to Data Streams Phase IV trials used to mean tracking long-term outcomes by continuing to... The post Modern Post-Market Trials Will Be Driven by RWD – Is Your EDC Ready? appeared first on Crucial Data Solutions.| Crucial Data Solutions
Real-world data and real-world evidence are important when it comes to cancer research because they can complement and expand findings from randomized clinical trials The post Real-world data 101: an overview appeared first on ECOG-ACRIN Advocacy Blog.| ECOG-ACRIN Advocacy Blog
This registry study is collecting real-world data on patients with advanced, EGFR-positive non-small cell lung cancer who may not have had the opportunity, wanted to, or been eligible to enroll in a trial The post Now Enrolling: This lung cancer patient registry study by PrECOG aims to better understand an FDA-approved treatment appeared first on ECOG-ACRIN Advocacy Blog.| ECOG-ACRIN Advocacy Blog
Givlaari safely led to a complete resolution of annual attacks in people with AHP, real-world data from a case series study in Italy shows.| Porphyria News
This innovative real-world data study is developing an infrastructure to conduct a study comparing outcomes in patients with EGFR-mutated NSCLC receiving osimertinib with or without chemotherapy and not enrolled in a clinical trial| News from the ECOG-ACRIN Cancer Research Group
